This study was the first to evaluate and compare the anti-fibrotic effects of the novel AT2R agonist, β-Pro7 Ang III [30], to the commonly used AT2R agonist, C21 [25,51], and the clinically approved TGF-β1 blocker, pirfenidone [12] in a murine model of BLM-induced pulmonary fibrosis. This evidence concerns the gene AGT and pulmonary fibrosis.